News | October 08, 2008

Datascope Sponsors Clinical Trial of Intra-Aortic Balloon Counterpulsation in Patients With Acute MI

October 9, 2008 - Datascope Corp. said today it will sponsor a 300-patient, randomized clinical trial in high-risk acute myocardial infarction (MI) patients who are not in cardiogenic shock to show the efficacy of intra-aortic balloon counterpulsation in reducing infarct size.

Patients enrolled in the CRISP AMI trial will be randomized equally to usual care versus usual care plus intra-aortic balloon counterpulsation (IABC) therapy prior to percutaneous coronary intervention. The primary efficacy endpoint will be a 25 percent reduction in infarct size due to IABC utilization. The successful completion of this trial represents a worldwide opportunity of more than 200,000 patients, or $200 million per year, the company said.

By targeting at-risk patients in this study, the aim is to significantly reduce infarct size, thereby improving myocardial salvage. Infarct size is a well-established surrogate clinical marker for patient mortality, congestive heart failure and quality of life.

The basis for the trial is a 2007 animal study. This study concluded that left ventricular unloading with IABC therapy prior to reperfusion reduces the extent of myocardial damage. These data suggest that in high-risk ST elevation myocardial infarction (STEMI) patients, IABP afterload reduction prior to reperfusion might be more beneficial than IABP placement post perfusion. This study was published in the October 2008 issue of Catheterization and Cardiovascular Interventions.

The trial will be conducted at approximately 30 sites in the U.S., Europe and Australia.

IABC therapy is currently the gold standard for a variety of clinical indications. It is a Class I indication for cardiogenic shock in the ACC/AHA guidelines.

For more information:

Related Content

Getinge Issues Worldwide Voluntary Correction of Maquet/Getinge Cardiosave Intra-Aortic Balloon Pump
News | Intra-Aortic Balloon Pumps (IABP) | September 24, 2018
September 24, 2018 — Getinge is voluntarily initiating a worldwide recall involving a field correction of approximate
Maquet Datascope Corp. is recalling the CardioSave Hybrid Intra-aortic Balloon Pump (IABP).

The touchscreen Maquet Datascope CardioSave Hybrid Intra-aortic Balloon Pump (IABP) system console.

News | Intra-Aortic Balloon Pumps (IABP) | June 06, 2018
June 6, 2018 — Maquet Datascope Corp.
An example of an intra-aortic balloon pump (IABP) from Maquet. The results of the SEMPER FI trial. #europcr2018 #Europcr

An example of an intra-aortic balloon pump (IABP) from Maquet. 

Feature | Intra-Aortic Balloon Pumps (IABP) | May 31, 2018
May 31, 2018 — The results from the Survival Improvement in Extensive Myocardial Infarction with PERsistent Ischemia
FDA Clears Teleflex Arrow AC3 Optimus Intra-Aortic Balloon Pump (IABP)
Technology | Intra-Aortic Balloon Pumps (IABP) | May 02, 2017
May 2, 2017 — The U.S. Food and Drug Administration (FDA) granted 510(k) clearance for the Teleflex Inc.
Impella CP heart pump, TCT 2016, intra-aortic balloon counterpulsation, IABP, clinical study
News | Intra-Aortic Balloon Pumps (IABP) | January 03, 2017 | Dave Fornell
The Impella CP heart pump (Abiomed) demonstrated no improvement in mortality for patients with myocardial infarction...
Teleflex, Arrow IAB catheter, intra-aortic balloon pump, worldwide recall
News | Intra-Aortic Balloon Pumps (IABP) | March 11, 2016
Teleflex Inc. announced the worldwide recall of Arrow International intra-aortic balloon catheter kits and percutaneous...